Total Funding
30
69
Total FundingGrant raised
Growth Score
1 pts
Heat Score
3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
126708
Avectas is a cell engineering technology company that enables drug developers to manufacture potent engineered cell therapies.
Shirley O'Dea: Co-Founder and Director, CSO- Justin McCue: Chief Technology OfficerPast Role: Repertoire Immune Medicines, Vice President, Technical Operations
About the Company
Avectas is a cell engineering technology company, enabling drug developers to manufacture potent engineered cell therapies at therapeutic volumes, with high efficiency and with minimal cell disruption. Avectas technology delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of cell types including T cells for
immuno-oncology applications. Unlike the current industry standard of vector-free delivery methods, cells engineered with Avectas technology require no recovery time, leading to a shorter, simpler, more cost effective process.
